Raje N, et al. Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma. N Engl J Med. 2019;380:1726–37. https://doi.org/10.1056/NEJMoa1817226.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Ruella M, Maus MV. Catch me if you can: Leukemia Escape after CD19-Directed T Cell Immunotherapies. Comput Struct Biotechnol J. 2016;14:357–62. https://doi.org/10.1016/j.csbj.2016.09.003.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Rosenthal J, et al. Heterogeneity of surface CD19 and CD22 expression in B lymphoblastic leukemia. Am J Hematol. 2018;93:E352–5. https://doi.org/10.1002/ajh.25235.

Article  PubMed  Google Scholar 

Lee H, et al. Mechanisms of antigen escape from BCMA- or GPRC5D-targeted immunotherapies in multiple myeloma. Nat Med. 2023;29:2295–306. https://doi.org/10.1038/s41591-023-02491-5.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Zhou Z, et al. The underlying mechanism of chimeric antigen receptor (CAR)-T cell therapy triggering secondary T-cell cancers: Mystery of the Sphinx? Cancer Lett. 2024;597: 217083. https://doi.org/10.1016/j.canlet.2024.217083.

Article  PubMed  CAS  Google Scholar 

Zhang, H. et al. Oncogenic viral antigens for engineered T cell immunotherapy: Challenges and opportunities. Medicine Advances 1, 306–317 (2023). https://doi.org/10.1002/med4.37

Schett G, Mackensen A, Mougiakakos D. CAR T-cell therapy in autoimmune diseases. Lancet. 2023;402:2034–44. https://doi.org/10.1016/s0140-6736(23)01126-1.

Article  PubMed  CAS  Google Scholar 

Zhang, W. et al. BCMA-CD19 bispecific CAR-T therapy in refractory chronic inflammatory demyelinating polyneuropathy. hLife 2, 434–438 (2024). https://doi.org/10.1016/j.hlife.2024.05.005

Kourelis T, et al. Ethical Challenges with Multiple Myeloma BCMA Chimeric Antigen Receptor T Cell Slot Allocation: A Multi-Institution Experience. Transplant Cell Ther. 2023;29:255–8. https://doi.org/10.1016/j.jtct.2023.01.012.

Article  PubMed  PubMed Central  Google Scholar 

Levine BL, Miskin J, Wonnacott K, Keir C. Global Manufacturing of CAR T Cell Therapy. Mol Ther Methods Clin Dev. 2017;4:92–101. https://doi.org/10.1016/j.omtm.2016.12.006.

Article  PubMed  CAS  Google Scholar 

Binder AF, Walker CJ, Mark TM, Baljevic M. Impacting T-cell fitness in multiple myeloma: potential roles for selinexor and XPO1 inhibitors. Front Immunol. 2023;14:1275329. https://doi.org/10.3389/fimmu.2023.1275329.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Thommen DS, Schumacher TN. T Cell Dysfunction in Cancer. Cancer Cell. 2018;33:547–62. https://doi.org/10.1016/j.ccell.2018.03.012.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Brudno JN, Kochenderfer JN. Off-the-shelf CAR T cells for multiple myeloma. Nat Med. 2023;29:303–4. https://doi.org/10.1038/s41591-022-02195-2.

Article  PubMed  CAS  Google Scholar 

Mansoori S, Noei A, Maali A, Seyed-Motahari SS, Sharifzadeh Z. Recent updates on allogeneic CAR-T cells in hematological malignancies. Cancer Cell Int. 2024;24:304. https://doi.org/10.1186/s12935-024-03479-y.

Article  PubMed  PubMed Central  Google Scholar 

Mishra, H. K. & Kalyuzhny, A. Revolutionizing Cancer Treatments through Stem Cell-Derived CAR T Cells for Immunotherapy: Opening New Horizons for the Future of Oncology. Cells 13 (2024). https://doi.org/10.3390/cells13181516

Zong, J. & Li, Y. R. iPSC Technology Revolutionizes CAR-T Cell Therapy for Cancer Treatment. Bioengineering (Basel) 12 (2025). https://doi.org/10.3390/bioengineering12010060

Liu Z, et al. Immunosuppression in tumor immune microenvironment and its optimization from CAR-T cell therapy. Theranostics. 2022;12:6273–90. https://doi.org/10.7150/thno.76854.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Maali A, et al. Nanobodies in cell-mediated immunotherapy: On the road to fight cancer. Front Immunol. 2023;14:1012841. https://doi.org/10.3389/fimmu.2023.1012841.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Zhou Z, et al. Emerging role of immunogenic cell death in cancer immunotherapy: Advancing next-generation CAR-T cell immunotherapy by combination. Cancer Lett. 2024;598: 217079. https://doi.org/10.1016/j.canlet.2024.217079.

Article  PubMed  CAS  Google Scholar 

Liu X, et al. Affinity-Tuned ErbB2 or EGFR Chimeric Antigen Receptor T Cells Exhibit an Increased Therapeutic Index against Tumors in Mice. Cancer Res. 2015;75:3596–607. https://doi.org/10.1158/0008-5472.CAN-15-0159.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Safarzadeh Kozani P, et al. Nanobody-based CAR-T cells for cancer immunotherapy. Biomark Res. 2022;10:24. https://doi.org/10.1186/s40364-022-00371-7.

Article  PubMed  PubMed Central  Google Scholar 

Volkel T, Korn T, Bach M, Muller R, Kontermann RE. Optimized linker sequences for the expression of monomeric and dimeric bispecific single-chain diabodies. Protein Eng. 2001;14:815–23. https://doi.org/10.1093/protein/14.10.815.

Article  PubMed  CAS  Google Scholar 

Hegde M, et al. Tandem CAR T cells targeting HER2 and IL13Ralpha2 mitigate tumor antigen escape. J Clin Invest. 2016;126:3036–52. https://doi.org/10.1172/JCI83416.

Article  PubMed  PubMed Central  Google Scholar 

Hirabayashi K, et al. Dual Targeting CAR-T Cells with Optimal Costimulation and Metabolic Fitness enhance Antitumor Activity and Prevent Escape in Solid Tumors. Nat Cancer. 2021;2:904–18. https://doi.org/10.1038/s43018-021-00244-2.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Majzner RG, et al. Tuning the Antigen Density Requirement for CAR T-cell Activity. Cancer Discov. 2020;10:702–23. https://doi.org/10.1158/2159-8290.CD-19-0945.

Article  PubMed  PubMed Central  CAS  Google Scholar 

El Khawanky N, et al. Demethylating therapy increases anti-CD123 CAR T cell cytotoxicity against acute myeloid leukemia. Nat Commun. 2021;12:6436. https://doi.org/10.1038/s41467-021-26683-0.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Wu, W. et al. Multiple Signaling Roles of CD3epsilon and Its Application in CAR-T Cell Therapy. Cell 182, 855–871 e823 (2020). https://doi.org/10.1016/j.cell.2020.07.018

Melenhorst JJ, et al. Decade-long leukaemia remissions with persistence of CD4(+) CAR T cells. Nature. 2022;602:503–9. https://doi.org/10.1038/s41586-021-04390-6.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Cappell KM, Kochenderfer JN. A comparison of chimeric antigen receptors containing CD28 versus 4–1BB costimulatory domains. Nat Rev Clin Oncol. 2021;18:715–27. https://doi.org/10.1038/s41571-021-00530-z.

Article  PubMed  CAS  Google Scholar 

Smith R, Shen R. Complexities in comparing the impact of costimulatory domains on approved CD19 CAR functionality. J Transl Med. 2023;21:515. https://doi.org/10.1186/s12967-023-04372-4.

Article  PubMed  PubMed Central  Google Scholar 

Huang R, et al. Recent advances in CAR-T cell engineering. J Hematol Oncol. 2020;13:86. https://doi.org/10.1186/s13045-020-00910-5.

Article  PubMed  PubMed Central